An Artemisia scoparia Extract and Rosiglitazone Have Distinct but Overlapping Effects on Adipocyte Function

Area of Science:

• Metabolism and Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Adipocyte function, insulin sensitivity, and lipolysis are crucial metabolic processes.
• Peroxisome proliferator-activated receptor gamma (PPARγ) plays a key role in regulating these processes.
• Artemisia scoparia extract (SCO) has demonstrated potential in modulating adipocyte function.

Purpose of the Study:

• To evaluate the actions of Artemisia scoparia extract (SCO) and rosiglitazone (ROSI) in adipocytes.
• To elucidate the role of PPARγ in the regulation of adipocyte function by SCO and ROSI.

Main Methods:

• Assessed PPARγ activation via half-life measurements and PPAR-dependent transcription assays.
• Measured glycerol release using siRNA gene silencing and pharmacological inhibition of PPARγ.
• Utilized immunoblotting for adiponectin and PDI detection, and RNA-seq for transcriptional profiling.

Main Results:

• Both SCO and ROSI enhanced PPARγ degradation, indicating ligand-induced activation.
• ROSI induced PPARγ transcriptional activity in three cell types, while SCO induced it in only one.
• SCO uniquely produced reduction-resistant adiponectin multimers and PDI complexes, with largely overlapping transcriptional pathways compared to ROSI.

Conclusions:

• SCO functions as a context-dependent PPARγ agonist with distinct effects on redox-dependent protein multimerization.
• Transcriptional profiling suggests SCO acts as a partial or selective PPARγ agonist.
• SCO exhibits unique molecular actions compared to the full agonist ROSI, indicating potential for targeted metabolic therapies.